Gene Therapy Latest News | Experimental Gene Therapy Studies

Roctavian, Potential Hemophilia A Gene Therapy, Get Fresh FDA Support

11 March 2021

Roctavian, Hem A Gene Therapy, Sustains Drop in Bleeding Rates, Phase 3 Data Show

13 January 2021

Gene Therapy SPK-8016 Shows Early Promise for Severe Hemophilia A

08 February 2021

BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set

10 January 2021

Non-viral Gene Therapy Shows Promise in Hemophilia A Animal Models
06 January 2021
Freeline Reports Updated Data From Phase 1/2 B-AMAZE Trial in Hemophilia B
14 December 2020
UniQure Shares Long-term Data About AMT-061 and AMT-060 Gene Therapy Candidates
09 December 2020
Gene Therapy AMT-060 for Hemophilia B Prevents Bleeds Up to 5 Years, Ongoing Trial Shows
03 December 2020

I agree with the Terms and conditions and the Privacy policy

About

Supported by educational grants from Bayer, BioMarin, Freeline Therapeutics Limited, Pfizer Inc., Shire, Spark Therapeutics, and uniQure, Inc.

Essential SSL